Pricing Log in Create free account

Cullinan Therapeutics, Inc. (CGEM) vs OmniAb, Inc. (OABI)

Cullinan Therapeutics, Inc. and OmniAb, Inc. are both Biotechnology companies. Cullinan Therapeutics, Inc. and OmniAb, Inc. are of similar size ($704.5M and $695.0M). Cullinan Therapeutics, Inc. has the higher net margin (0.00% vs −108.1%) and the higher return on invested capital (0.00% vs −15.8%). Across the 12 metrics below, OmniAb, Inc. leads on 7 and Cullinan Therapeutics, Inc. on 5.

Valuation

Metric CGEM OABI Biotechnology median
P/E n/m n/m 10.60
P/S n/m 16.14 9.40
P/B 2.17 2.61 2.13
Price to free cash flow n/m 272.71 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 14.54 9.02
Earnings yield (27.34%) (6.77%) (32.88%)
Free cash flow yield (22.84%) 0.37% (23.13%)

Profitability

Metric CGEM OABI Biotechnology median
Gross margin — 97.65% 68.51%
Operating margin 0.00% (115.89%) 0.00%
Net margin 0.00% (108.11%) 0.00%
Free cash flow margin 0.00% 5.92% 0.00%
Return on equity (50.30%) (16.51%) (51.96%)
Return on assets (46.30%) (14.48%) (46.06%)
Return on invested capital 0.00% (15.75%) 0.00%

Growth

Metric CGEM OABI Biotechnology median
Revenue growth (TTM) — 90.63% 6.76%
EPS growth (last fiscal year) (20.86%) 6.56% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CGEM OABI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.42 4.21 4.97
Net debt to EBITDA 1.57 1.12 1.01

Dividend

Metric CGEM OABI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CGEM OABI Biotechnology median
Market cap 695.03m 704.51m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack